NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide & Dexamethasone RRMM
Updated: Sep 26, 2022
NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
This is a randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI).
Eligible participants will be randomized 1:1 into 1 of 2 study arms:
Arm SC: Isatuximab SC + Pd
Arm IV: Isatuximab IV + Pd
Participants will be allowed to continue therapy until disease progression, unacceptable adverse events (AEs), participant request to discontinue therapy or any other reason, whichever comes first.
ClinicalTrials.gov Identifier: NCT05405166
Official Title: A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
First Posted : June 6, 2022
Click here to see details on ClinicalTrials.gov
Dexamethasone : National Cancer Institute
Isatuximab : National Cancer Institute
Pomalidomide : National Cancer Institute
Drug: Isatuximab IV